{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T05:04:42Z","timestamp":1733461482395,"version":"3.30.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.urolonc.2023.08.007","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:08:20Z","timestamp":1694696900000},"page":"454.e17-454.e24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5138-3190","authenticated-orcid":false,"given":"Andreas","family":"Boehle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothea","family":"Zywietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Robrahn-Nitschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Lusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inke R.","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2023.08.007_bib0001","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.11.022","article-title":"Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer","volume":"36","author":"King","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0003","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0004","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0005","first-page":"583","article-title":"NCCN guidelines updates: management of prostate cancer","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0006","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0007","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ijrobp.2007.01.039","article-title":"Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer","volume":"68","author":"Lee","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0008","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.eururo.2012.02.055","article-title":"A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens","volume":"62","author":"Fine","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0009","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0010","unstructured":"Schaeffer EM. NCCN clinical practice guidelines in oncology (NCCN Guidelines \u00ae) prostate cancer. 2022."},{"key":"10.1016\/j.urolonc.2023.08.007_bib0011","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.eururo.2005.06.001","article-title":"EAU guidelines on prostate cancer","volume":"48","author":"Aus","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0012","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s00345-019-02649-2","article-title":"Combined-modality (125)J-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: report of outcomes and side-effects","volume":"37","author":"Boehle","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0013","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2011.07.005","article-title":"American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy","volume":"11","author":"Davis","year":"2012","journal-title":"Brachytherapy."},{"key":"10.1016\/j.urolonc.2023.08.007_bib0014","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0302-2838(02)00018-0","article-title":"Importance of post-implant dosimetry in permanent prostate brachytherapy","volume":"41","author":"Stock","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cncr.23139","article-title":"The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer","volume":"112","author":"Abramowitz","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0016","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0017","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.eururo.2015.10.029","article-title":"Clinical utility of quantitative Gleason grading in prostate biopsies and prostatectomy specimens","volume":"69","author":"Sauter","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0018","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma","volume":"29","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol."},{"key":"10.1016\/j.urolonc.2023.08.007_bib0019","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0020","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.brachy.2021.07.006","article-title":"Low dose rate brachytherapy for primary treatment of localized prostate cancer: a systemic review and executive summary of an evidence-based consensus statement","volume":"20","author":"King","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0021","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.brachy.2019.10.005","article-title":"Validation of the NCCN prostate cancer favorable-and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy","volume":"19","author":"Tom","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0022","doi-asserted-by":"crossref","first-page":"430","DOI":"10.5114\/jcb.2015.56763","article-title":"Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts","volume":"7","author":"Merrick","year":"2015","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0023","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/j.clgc.2020.11.003","article-title":"Improving the stratification of patients with intermediate-risk prostate cancer","volume":"19","author":"Stolzenbach","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0024","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.eururo.2019.09.027","article-title":"Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study","volume":"77","author":"Zelic","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0025","doi-asserted-by":"crossref","first-page":"E120","DOI":"10.1111\/bju.12771","article-title":"Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature","volume":"114","author":"Faisal","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0026","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with gleason score 9-10 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0027","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2016.06.046","article-title":"Clinical outcomes for patients with Gleason score 9-10 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis","volume":"71","author":"Kishan","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0028","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.brachy.2018.08.008","article-title":"Using a surgical prostate-specific antigen threshold of >0.2 ng\/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial","volume":"17","author":"Morris","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0029","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.brachy.2016.11.017","article-title":"American Brachytherapy Society Task Group Report: use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review","volume":"16","author":"Keyes","year":"2017","journal-title":"Brachytherapy."},{"key":"10.1016\/j.urolonc.2023.08.007_bib0030","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.ijrobp.2016.12.014","volume":"97","author":"Ciezki","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2023.08.007_bib0031","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.juro.2014.03.094","article-title":"15-year cause specific and all-cause survival following brachytherapy for prostate cancer: negative impact of long-term hormonal therapy","volume":"192","author":"Stone","year":"2014","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392300282X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392300282X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T04:22:42Z","timestamp":1733372562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392300282X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S107814392300282X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.08.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}